Study aid only. Verify against current guidelines before clinical use.

All 1,600+ trial summaries

Trials · GI Cancer · Colon - advanced

KEYNOTE-177

Andre T et al, NEJM, 2020; PMID: 33264544

Summarized and reviewed by Veli Bakalov, MD · Updated

Medical OncologyGI CancerColon - advanced2023

At a glance

First-line pembrolizumab improved PFS with less toxicity than chemotherapy, establishing immunotherapy as a 1L standard in MSI-H/dMMR mCRC.

Population
307 treatment-naive patients with metastatic MSI-H/dMMR colorectal cancer
Design
Phase III RCT
Arms
Pembrolizumab 200 mg Q3W vs mFOLFOX6 or FOLFIRI with or without bevacizumab or cetuximab
Primary endpoint
PFS and OS
Key result
mPFS 16.5 vs 8.2 mo, HR 0.60, 95% CI 0.45-0.80, P=.0002; OS HR 0.74, 95% CI 0.53-1.03 (did not cross prespecified threshold)
Background
Phase III RCT of 307 treatment-naive patients with metastatic MSI-H/dMMR colorectal cancer.
Interventions and follow up
Arm A: Pembrolizumab 200 mg IV Q3W (up to 35 cycles)
Arm B: Investigator-choice chemotherapy (mFOLFOX6 or FOLFIRI) with or without bevacizumab or cetuximab
Primary endpoints: Progression-free survival (PFS) and overall survival (OS)
mFollow up: 32.4 mo (PFS analysis)
Results
mPFS: 16.5 mo (Arm A) vs 8.2 mo (Arm B); HR 0.60, 95% CI 0.45–0.80; P=.0002
ORR: 43.8% vs 33.1%, with more durable responses in the pembrolizumab arm
OS (final analysis): mOS not reached vs 36.7 mo; HR 0.74, 95% CI 0.53–1.03; P=.036 (did not cross prespecified threshold, confounded by crossover)
Adverse events
Treatment-related (grade ≥3, A vs B): 22% vs 66%
Immune-mediated (any grade, A vs B): 31% vs 13%; serious immune-mediated events were uncommon
Discontinuation: Lower with pembrolizumab
Conclusions
First-line pembrolizumab significantly improved PFS versus chemotherapy with a favorable safety profile in patients with MSI-H/dMMR metastatic colorectal cancer, establishing immunotherapy as a 1L standard in this molecular subset.
Key Limitations
OS interpretation confounded by ~60% crossover from chemotherapy to anti-PD-1; early progression in a subset of pembrolizumab patients (early crossing of survival curves); applies only to the MSI-H/dMMR subset (~5% of mCRC).
Clinical Context
KEYNOTE-177 led to FDA (2020) and EMA approval of first-line pembrolizumab for MSI-H/dMMR mCRC, making it the ESMO-preferred 1L option for this biomarker-selected group. It underscores the need for universal MMR/MSI testing at diagnosis; dual checkpoint blockade (nivolumab/ipilimumab, CheckMate 8HW) is an emerging alternative.
References
André et al, NEJM, 2020, PMID: 33264544
Diaz LA Jr et al, Lancet Oncol, 2022 (final OS), PMID: 35345594
Open in the interactive trials browser View source ↗
HemeOncBuddy Clinical Trials Pivotal trial summaries in hematology and oncology Browse 1,600+ summaries by disease, filter by area or search by drug. Open all trial summaries